Across its top 20 institutional holders, QTTB's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 29/100, avg. turnover score 37/100).

Quarterly Activity

Recent Activity

+$16.2M

Total Buy Value

$3.5M

Total Sell Value

New buy9

Trim9

Add14

Sold out8

Net Buyers

Net Sellers

Smart Money Convergence

QTTB does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-15

2026-07-15

Q32 Bio (ticker QTTB) entered into an underwriting agreement on July 14, 2026, to sell about 6 million shares at $18.25 each and about 4.9 million pre-funded warrants at $18.2499 each, raising roughly $187.6 million (or up to $215.8 million if underwriters take the extra shares). The company will use the proceeds for working capital and to fund research, clinical development, and commercialization, including advancing its drug bempikibart into future trials. The offering is expected to close on July 16, 2026.

View Full Filing (SEC EDGAR)

2026-07-13

Q32 Bio Inc. issued a press release on July 13, 2026, announcing positive 36-week results from its SIGNAL-AA clinical trial. The disclosure was made under Regulation FD.

View Full Filing (SEC EDGAR)

2026-07-13

Q32 Bio Inc. announced topline results from Part B of its SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. The company filed a presentation related to the announcement as an exhibit to this 8-K with the SEC. The filing does not include the specific data, but the presentation is available for review.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

746964105

FAQ

Who are the top institutional investors holding Q32 BIO INC (QTTB)?

Major stakeholders currently include Orbimed Advisors LLC ($14.5M), Atlas Venture Life Science Advisors, LLC ($13.4M), Opaleye Management Inc. ($8.1M). Based on the latest 13F filings, there are a total of 53 tracked investment funds and institutions maintaining positions in QTTB.

What is the overall institutional sentiment toward QTTB recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $34.0M, driven by 23 managers accumulating shares while 17 reduced their exposure.

Which institutions have been selling or reducing their QTTB positions?

In the latest period, 9 funds trimmed their holdings, and 8 managers completely exited their positions. The aggregate reported sell value was $3.5M.

Are there any notable investors adding QTTB to their portfolios?

Yes, buying activity remains notable. 9 institutions opened new positions in {ticker}, and 14 existing holders added to their shares. The total reported buy value for the quarter amounted to $16.2M.